Marconi Medical Systems Gets FDA Clearance for Large-Bore Oncology CT Scanner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

CLEVELAND-Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

CLEVELAND—Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

The ACQSIM CT scanner is designed with an 85-cm large bore, to simplify planning difficult cases, including breast, Hodgkin’s lymphoma, and large patients.

The acQsim system includes a high-precision localization and marking system and a virtual simulator that yield digitally composited and/or reconstructed radiographs that exceed the requirements of conformal and high-precision radiotherapy delivery, the company said.

The footprint of the new scanner is the same as that of standard 70-cm diagnostic CTs and is designed to fit into rooms that currently house a conventional simulator or CT scanner.

Several sites will be installed in 2000, the company said, with general product release scheduled for the spring of 2001.

Recent Videos
2 experts are featured in this series.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content